Evonik (Essen, Germany) recently announced that has purchased JeNaCell and its nanostructured biomaterial for wound dressings and dermatology.
The financial terms of the deal were not disclosed.
JeNaCell (Jena, Germany) provides biotechnologically derived cellulose. Evonik first invested in the startup in 2015.
“JeNaCell has developed one of the most innovative biomaterials for medical device technologies. With the help of the creativity and expertise of JeNaCell’s specialists, we will ensure that even more patients benefit from these products in the future,” said Thomas Riermeier, head of Evonik’s Health Care business line, said in an Aug. 2 news release. “The acquisition will help us to further strengthen our position as an innovation hub for the world’s leading medical technology companies.”